Professor Chris Fegan

2024

• Fegan, G. et al., 2024. Social deprivation independently impacts clinical outcomes in patients with chronic lymphocytic leukemia. Haematologica 109 (5)(10.3324/haematol.2023.283527)

2023

• Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186 (16), pp.3333-3349. E27. (10.1016/j.cell.2023.06.020)

2022

• Burley, T. A. et al., 2022. Elucidation of focal adhesion kinase as a modulator of migration and invasion and as a potential therapeutic target in chronic lymphocytic leukemia. Cancers 14 (7) 1600. (10.3390/cancers14071600)

2021

• Alsagaby, S. A. et al. 2021. Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. Electronic Journal of Biotechnology 52 , pp.1-12. (10.1016/j.ejbt.2021.04.006)
• Kennedy, E. et al., 2021. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood 137 (22), pp.3064-3078. (10.1182/blood.2020005964)
• Lewis, T. et al. 2021. Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers. Haematologica 106 (4), pp.958-967. (10.3324/haematol.2019.238584)
• Moat, S. J. et al. 2021. Development of a high throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Annals of Clinical Biochemistry 58 (2)(10.1177/0004563220981106)

2020

• Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202 (9), pp.1304-1308. (10.1164/rccm.202007-2778LE)
• O'Donnell, V. B. et al. 2020. Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function 1 (1) zqaa002. (10.1093/function/zqaa002)
• Rule, S. A. et al., 2020. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059) [Letter]. Leukemia 34 , pp.1458-1461. (10.1038/s41375-019-0658-7)
• Elston, L. et al. 2020. Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL. British Journal of Haematology 188 (6), pp.872-880. (10.1111/bjh.16260)
• Pepper, C. , Norris, K. and Fegan, C. 2020. Clinical utility of telomere length measurements in cancer. Current Opinion in Genetics and Development 60 , pp.107-111. (10.1016/j.gde.2020.02.012)

2019

• Cohen, J. A. et al., 2019. A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. Haematologica 104 (11) 228171. (10.3324/haematol.2019.228171)
• Escudero, L. et al., 2019. Telomere fusions associate with coding sequence and copy number alterations in CLL. Leukemia 33 , pp.2093-2097. (10.1038/s41375-019-0423-y)
• Norris, K. et al. 2019. Telomere length predicts for outcome to FCR chemotherapy in CLL. Leukemia 33 , pp.1953-1963. (10.1038/s41375-019-0389-9)

2018

• Went, M. et al., 2018. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer Journal 9 1. (10.1038/s41408-018-0162-8)

2017

• Hyatt, S. et al. 2017. Telomere length is a critical determinant for survival in multiple myeloma. British Journal of Haematology 178 (1), pp.94-98. (10.1111/bjh.14643)
• Williams, J. et al., 2017. Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology 178 (2), pp.240-249.
• Law, P. J. et al., 2017. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications 8 14175. (10.1038/ncomms14175)
• Law, P. J. et al., 2017. Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Scientific Reports 7 41071. (10.1038/srep41071)
• Pepper, C. J. et al. 2017. Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor. Oncotarget (10.18632/oncotarget.14545)

2016

• Pasikowska, M. et al., 2016. Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. Blood 128 (4), pp.563-573. (10.1182/blood-2016-01-683128)
• Parry, H. M. et al., 2016. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia. American Journal of Hematology 91 (8), pp.776-781. (10.1002/ajh.24403)

2015

• Nichols, E. et al., 2015. A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL. Oncotarget 6 (32), pp.32669-32680. (10.18632/oncotarget.5404)
• Pepper, C. et al. 2015. Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition. Leukemia 29 , pp.744-747. (10.1038/leu.2014.308)
• Sava, G. P. et al., 2015. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia 29 , pp.748-751. (10.1038/leu.2014.311)
• Reid, R. et al. 2015. CD8+ T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology 144 (3), pp.495-505. (10.1111/imm.12398)
• Fegan, C. D. and Pepper, C. J. 2015. Understanding cancer cell survival is key to patient survival. The Lancet Oncology 16 (2), pp.122-124. (10.1016/S1470-2045(15)70003-3)

2014

• Walsby, E. et al. 2014. Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. Blood 123 (23), pp.3607-3617. (10.1182/blood-2013-12-544569)
• Bulian, P. et al., 2014. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. Journal of Clinical Oncology 32 (9), pp.897-904. (10.1200/JCO.2013.50.8515)
• Alsagaby, S. A. et al., 2014. Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. Journal of Proteome Research 13 (11), pp.5051-5062. (10.1021/pr5002803)
• Lin, T. T. et al., 2014. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British Journal of Haematology 167 (2), pp.214-223. (10.1111/bjh.13023)
• Pepper, C. J. , Baird, D. M. and Fegan, C. D. 2014. Telomere analysis to predict chronic lymphocytic leukemia outcome: a STELA test to change clinical practice?. Expert Review of Hematology 7 (6), pp.701-703. (10.1586/17474086.2014.969705)

2013

• Wong, R. F. et al. 2013. Blinatumomab induces autologous T cell killing of chronic lymphocytic leukemia cells. Haematologica 98 (12), pp.1930-1938. (10.3324/haematol.2012.082248)
• Groves, M. et al., 2013. p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia. British Journal of Cancer 109 (9), pp.2434-2444. (10.1038/bjc.2013.601)
• Chubb, D. et al., 2013. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nature Genetics 45 (10), pp.1221-1225. (10.1038/ng.2733)

2012

• Walsby, E. J. et al. 2012. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget 3 (5), pp.525-534.

2011

• Watkins, C. L. et al., 2011. Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8. Molecular Therapy 19 (12), pp.2124-2132. (10.1038/mt.2011.175)

2010

• Crowther-Swanepoel, D. et al., 2010. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nature Genetics 42 (2), pp.132-136. (10.1038/ng.510)
• Pourgheysari, B. et al., 2010. The number of cytomegalovirus-specific CD4+ T cells is markedly expanded in patients with B-cell chronic lymphocytic leukemia and determines the total CD4+ T-cell repertoire. Blood 116 (16), pp.2968-2974. (10.1182/blood-2009-12-257147)

2007

• Pepper, C. J. et al. 2007. Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia 21 (4), pp.687-696. (10.1038/sj.leu.2404587)

1999

• Brown, S. A. et al., 1999. Haemostatic and fibrinolytic responses to bone marrow transplantation. British Journal of Haematology 104 (3), pp.468-474. (10.1046/j.1365-2141.1999.01223.x)

1998

• Brown, S. A. et al., 1998. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplantation 22 (3), pp.281-284. (10.1038/sj.bmt.1701321)

1996

• Brown, S. A. et al., 1996. A biphasic haemostatic response during bone marrow transplantation [Abstract]. Blood 88 (10), pp.1638.

1994

• Poynton, C. H. et al. 1994. Aberrant durface phenotype in MDS confers a poor-prognosis with more rapid development of AML [Abstract]. Blood 84 (10), pp.A316.

1993

• Jackson, S. K. et al., 1993. Effect of IgM-enriched intravenous immunoglobulin (Pentaglobin) on endotoxaemia and anti-endotoxin antibodies in bone marrow transplantation. European Journal of Clinical Investigation 23 (9), pp.540-545. (10.1111/j.1365-2362.1993.tb00963.x)

1992

• Poynton, C. H. et al. 1992. Use of IgM enriched intravenous immunoglobulin (Pentaglobin) in bone marrow transplantation. Bone Marrow Transplantation -Basingstoke then London- 9 (6), pp.451-457.